Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Acupuncture needle with lidocaine may ease migraines

NCT ID NCT07067853

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested whether injecting lidocaine into the GB20 acupoint (at the back of the neck) can reduce migraine attacks. Thirty adults with migraines received either weekly lidocaine injections for four weeks or daily propranolol pills. Researchers tracked headache frequency, duration, pain intensity, and disability over two months to see if the injections work as well as standard medication.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
lidocaine 2% injection at GB20 acupoint
What this could lead to
If it works, this could offer a safe, non-oral alternative for migraine relief with fewer daily pills.
What could go wrong
This is a small, completed trial with only 30 participants, so results may not apply widely. Lidocaine injections can cause pain, infection, or skin irritation at the injection site.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

30 people

The number who actually took part.

Started

Sep 2025

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 59 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosed with migraine * Minimum of 3 days of migraine attacks in 1 month * Willing to participate until the study concludes Exclusion Criteria: * Headache with other known cause (e.g. head trauma, cancer, hemorrhagic stroke) * Inaccessible GB20 acupuncture point (scar tissue, infection, open wound, etc) * History of heart disease and/or asthma * History of Hypersensitivity with propranolol and/or lidocaine * History of acupuncture treatment 3 month prior to study * Routine consumption of anticoagulation medications, steroids or pain killers * Pregnant and breastfeeding women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Migraine are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Universitas Indonesia

    Jakarta Pusat, DKI Jakarta, 10430, Indonesia

More trials for these conditions

Other studies related to the condition(s) this trial covers.